Thought this study (link below and full text provisional article is attached) would be of interest especially given that countries are being called upon to scale up ART services. An observational cohort study done in Dodoma Tanzania found an estimated prevalence rate of 12% resistance to primary drugs and 7.5% to NNRTIs among ART naïve HIV-infected pregnant women. What implications will this have for policy makers especially in low resource settings as programs scale up? How can policy makers mitigate this or better monitor the quality of ART programs?
Your insights are greatly appreciated.
Link leads to: http://www.biomedcentral.com/1471-2334/13/439/abstract
Link leads to: http://www.biomedcentral.com/content/pdf/1471-2334-13-439.pdf